GLP-1 prior authorization: a step-by-step that actually works in 2026

TLDR. Insurance prior authorization is the single most common reason patients give up on the brand GLP-1 route. About 30 to 40 percent of initial PAs are denied. The most reliable winning path: BMI of 30 or higher (or 27 to 29.9 with a qualifying comorbidity), 6 months of documented lifestyle modification with weight measurements in chart, comorbidity ICD-10 codes attached, and a prescriber letter addressing the specific PBM checklist. Roughly half of denials are reversed on appeal. The deciding factor is rarely the patient; it is the documentation the prescriber submits.

If your employer plan covers GLP-1 medications for weight loss, you can drop your monthly cost from $400-$1,000 cash to a $25-$50 copay. That is the difference between affording it for one year and affording it forever.

The catch is prior authorization. PA is the insurance company's "prove it" gate, and most plans require it before they will pay for a single dose of Wegovy or Zepbound. The PA forms are not consumer-friendly and the criteria differ by plan. This is the actual step-by-step that gets approvals in 2026.

If you just want the letter your prescriber needs to send, jump to our PA letter library: 60 plan-and-condition letter templates for the 10 largest US health plans.

Step 1: confirm coverage exists at all

Before you do anything else, find your plan's formulary. Look for "Wegovy" and "Zepbound" by exact brand name. Both are typically listed in Tier 3 or Tier 4 with PA required.

If you cannot find either drug on your formulary, your plan does not cover GLP-1 for weight loss. Some plans cover them only for type 2 diabetes (Ozempic, Mounjaro), in which case you need a diabetes diagnosis, not an obesity diagnosis. Read the next section carefully if you fall into this category.

Step 2: confirm the diagnostic criteria

Most plans require all four of these for weight-loss GLP-1 approval:

• BMI of 30 or higher (obesity), OR BMI of 27-29.9 with at least one obesity-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, sleep apnea)
• Documented prior attempts at weight loss through diet and exercise, typically over 6 months
• Documented prior attempts with other anti-obesity medications, sometimes specified by name
• An obesity-medicine prescriber, sometimes a specialist, sometimes a PCP

The 6-month diet-and-exercise documentation trips up the most patients. Plans want either a structured weight-management program (think WeightWatchers, Noom, a hospital-based program) or a documented 6-month treatment plan with your PCP that includes nutrition, exercise and behavioral counseling. Self-reported attempts do not count.

Step 3: pick the right program

The single biggest factor in whether a PA gets approved is whether your prescriber knows how to write the PA letter. Some telehealth programs are excellent at this; some refuse to do it at all.

From our chart, the programs that actively run prior auth and have measurable approval rates are:

• PlushCare (uses your real insurance, in-network with most major carriers, will run PA on Wegovy and Zepbound)
• Form Health (obesity-medicine specialists, will write the comorbidities letter, takes insurance)
• Knownwell (full primary-care integration, handles PA as standard practice)
• 9amHealth (specifically targets patients with metabolic comorbidities)

Compounded-only programs like Mochi and Henry Meds will not run PA on branded drugs. That is by design; their model is cash-pay compounded.

Step 4: gather your documentation

You need three things in your PA packet:

1. Height, weight, BMI, ideally from a recent measurement in your medical record
2. Comorbidity documentation: ICD-10 codes from your prior visits showing hypertension (I10), type 2 diabetes (E11.9), dyslipidemia (E78.5), sleep apnea (G47.33) or others. Your prescriber pulls these
3. Prior weight-loss attempt documentation: any visit notes that mention dietary counseling, exercise prescription, behavioral therapy or prior anti-obesity medications (orlistat, phentermine, naltrexone-bupropion, liraglutide)

Step 5: submit the PA and wait

Standard PA turnaround is 5-15 business days. Urgent PAs (which require your prescriber to attest that delay would harm you) turn around in 24-72 hours.

For most obesity PAs, the urgent route is not appropriate. Set expectations for 1-3 weeks. Do not start ordering compounded as a bridge until you have the PA decision.

Step 6: if you are denied, appeal

Initial denials happen on roughly 30-40% of GLP-1 PAs based on industry data. Most denials are appealable, and approximately half of appeals succeed.

The two most common denial reasons:

• "Insufficient documentation of prior weight-loss attempts." Appeal by submitting visit notes showing dietary counseling, exercise prescriptions or prior medication trials, even if those happened years ago.
• "Step therapy required." The plan wants you to fail on a cheaper drug first, usually phentermine or contrave. Either run the step therapy (4-12 weeks of phentermine, document it, then re-apply for the GLP-1) or have your prescriber write a "medical necessity" letter explaining why phentermine is contraindicated for you.

The appeal letter is the prescriber's job, not yours. If your prescriber will not write one, switch prescribers.

Step 7: refill PAs annually

PA approvals usually last 12 months. Set a calendar reminder for month 11 so your prescriber can renew before the lapse. Renewals are easier than initial PAs because you can attach weight-loss data showing the drug is working.

What it costs you in time

End to end, expect 4-8 weeks from "I want to try Wegovy" to "my first script lands." That timeline drops to 1-2 weeks if you already have the comorbidity documentation and an obesity-medicine prescriber in your record.

If 4-8 weeks is unacceptable, the compounded cash-pay path through Mochi or Henry Meds gets you on medication in 2-5 days. The trade-off is paying $100-$250/month indefinitely versus $25-$50 copay once the PA clears.

See our list of insurance-friendly programs or compare PlushCare and Form Health head-to-head.

Get the actual letter your clinician sends

The piece that trips up most patients is not understanding the process. It is the letter itself. We maintain a PA letter library with 60 templates covering the 10 largest US health plans and the 6 qualifying indications. Each template cites the plan's actual policy document, the ICD-10 codes, the registration-trial evidence and the criteria checklist. Free, no email gate. If you already got denied, the appeal letter library has 60 denial-specific rebuttals.

Frequently asked questions

What does insurance want to see for GLP-1 prior authorization?

Five elements. BMI of 30 or higher, or BMI 27 to 29.9 with a qualifying comorbidity (hypertension, T2D, dyslipidemia, OSA, ASCVD). Documented lifestyle modification (diet, exercise, behavioral therapy) across a 6-month window with measured weights in chart. No contraindications (personal or family MTC, MEN2, pancreatitis, gastroparesis, pregnancy). Prescriber attestation. For Zepbound at some plans, failed semaglutide trial.

How long does PA take?

Standard timeline is 2 to 14 business days. CVS Caremark averages 5 to 7 days, OptumRx 7 to 10, Express Scripts 5 to 10. Urgent PAs (clinical justification for expedited review) decide in 72 hours. The clock starts when the prescriber submits the complete PA, not when the prescription is written.

What if my PA is denied?

Read the denial letter for the specific reason. The most common reasons (insufficient lifestyle docs, missing comorbidity codes, step-therapy failures) are all fixable. File a Level 1 appeal with the missing documentation; success rate is roughly 50 percent. If Level 1 fails, Level 2 (independent review) and Level 3 (external review) are available.

Which programs handle PA well?

PlushCare, Form Health, Knownwell, 9amHealth all run PA as standard practice with documentation infrastructure built for it. Form Health (obesity-medicine specialists) writes detailed comorbidity letters. Compounded-only programs like Mochi and Henry Meds will not run PA on branded drugs; that is the cash-pay model.

Does Medicare cover GLP-1 under prior authorization?

Medicare Part D does not cover anti-obesity medications under a statutory exclusion. Two exceptions: Wegovy for cardiovascular risk reduction in established CVD (added 2024 after SELECT), and Ozempic or Mounjaro for type 2 diabetes under standard T2D criteria. The PA path runs through the diabetes or CVD diagnosis, not obesity.